Drugs to avoid in pregnancy

Current Obstetrics and Gynaecology

Volumn 10, Issue 1, 2000, Pages 44-52

  Shehata, H A ^a   Nelson Piercy, C ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; CARDIOVASCULAR AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DAPSONE; ETRETINATE; ISOTRETINOIN; MEFLOQUINE; METHOTREXATE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PSYCHOTROPIC AGENT; SEX HORMONE; STATIN; THALIDOMIDE;

DRUG USE; FETUS; FETUS MALFORMATION; HUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; REVIEW; TERATOGENICITY;

EID: 0034126701     PISSN: 09575847     EISSN: None     Source Type: Journal    
DOI: 10.1054/cuog.2000.0104     Document Type: Review

References (65)

1. Buitendijk S., Bracken M. B. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol. 165:1991;33-40.
2. Rubin P. C. Prescribing in pregnancy. General principles. Br Med J. 293:1986;1415-1417.
3. Forfar J. O., Nelson M. M. Epidemiology of drugs taken by pregnant women: drugs that may affect the fetus adversely. Clin Pharmacol Ther. 14:1973;632-642.
4. Passmore C. M., McElnay J. C., D'Arcy P. F. Drugs taken by mothers in the puerperium: inpatient survey in Northern Ireland. Br Med J. 289:1984;1593-1596.
5. Dunlop W. Investigations into the influence of posture on renal plasma flow and glomerular filtration rate during late pregnancy. Br J Obstet Gynaecol. 83:1976;17-23.
6. Moore K. L. The developing human: clinically oriented embryology, 4th edn. 1988;W.B Saunders. Philadelphia. p. 131.
7. Ekelund H., Kullander S., Kallen B. Major and minor malformations in newborns and infants up to one year of age. Acta Paed Scand. 59:1970;297-302.
8. Ash P., Vennart J., Carter C. O. The incidence of hereditary disease in man. J Med Genet. 14:1977;305.
9. Rubin P. C. General principles. Rubin P. C. Prescribing in pregnancy, 2nd edn. 1995;1-8 BMJ Publishing, London.
10. Ostensen M., Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Safety. 19:1998;389-410.
11. Bermas B. L., Hill J. A. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 38:1995;1722-1732.
12. Koren G., Pastuszak A., Ito S. Drugs in pregnancy. N Engl J Med. 338:1998;1128-1137.
13. Fantel A. G., Shepard T. H., Newell-Morris L. L. Teratogenic effects of retinoic acid in pigtail monkeys (Macaca nemestrina) I. General features. Teratology. 15:1977;65-71.
14. Lammer, E. J. Chen, D. T. Hoar, R. M. N Engl J Med, 1985, 313, 837, 841.
15. Nora J. J., Nora A. H., Toews W. H. Lithium, Ebstein's anomaly, and other congenital heart defects. Lancet. 2:1974;594-595.
16. Jacobson S. J., Jones K., Johnson K. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet. 339:1992;530-533.
17. Schardein J. L. Chemically induced birth defects, 2nd edn. 1993;Marcel Dekker, New York.
18. Kotoh T., Dhar D. K., Masunaga R. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery. 125:1999;536-544.
19. Larkin M. Low-dose thalidomide seems to be effective in multiple myeloma. Lancet. 354:1999;925.
20. Duong D. J., Spigel G. T., Moxley R. T. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol. 135:1999;1079-1087.
21. Shek L. P., Lee Y. S., Lee B. W. Thalidomide responsiveness in an infant with Behcet's syndrome. Pediatrics. 103:1999;1295-1297.
22. Fife K., Howard M. R., Gracie F. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS. 9:1998;751-755.
23. Rosa F. W., Bosco L. A., Graham C. F. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol. 74:1989;371-374.
24. Steffensen F. H., Nielsen G. L., Sorensen H. T. Pregnancy outcome with ACE-inhibitor use in early pregnancy. Lancet. 351:1998;596.
25. JAMA. 277:1997;1193-1194.
26. Messina M., Biffignandi P., Ghigo E. Possible contraindication of spironolactone during pregnancy. J Endocrinol Invest. 2:1979;222.
27. Rose L. I., Regestein Q., Reckler J. M. Lack of effect of spironolactone on male genital development. Investigative Urology. 13:1975;95-96.
28. Ostensen M. Nonsteroidal anti-inflammatory drugs during pregnancy. Scand J Rheumatol. 27 Suppl 107:1998;128-132.
29. Stuart M. J., Gross S. J., Elrad H. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med. 307:1982;909-912.
30. Vanhaesebrouck P., Thiery M., Leroy J. G. Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J Pediatr. 113:1988;738-743.
31. Niebyl J. R., Witter F. R. Neonatal outcome after indomethacin treatment for preterm labor. Am J Obstet Gynecol. 155:1986;747-749.
32. Ayub M., Stitch S. R. Effect of ketoconazole on placental aromatase, 3 beta-hydroxysteroid dehydrogenase-isomerase and 17 beta-hydroxysteroid dehydrogenase. Journal of Steroid Biochem. 25:1986;981-984.
33. Berwaerts J., Verhelst J., Mahler C., Abs R. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecological Endocrinology. 13:1999;175-182.
34. Gupta A. K., Shear N. H. Terbinafine: an update. J Am Acad Dermatol. 37:1997;979-988.
35. O'Doherty M. J., McElhatton P. R., Thomas S. H. Treating thyrotoxicosis in pregnant or potentially pregnant women. Br Med J. 318:1999;5-6.
36. Rosa F. W. Virilization of the female fetus with maternal danazol exposure. Am J Obstet Gynecol. 149:1984;99-100.
37. Marcus W. L. Lithium: a review of its pharmacokinetics, health effects, and toxicology. J Environ Pathol Toxicol Oncol. 13:1994;73-79.
38. Troyer W. A., Pereira G. R., Lannon R. A. Association of maternal lithium exposure and premature delivery. J Perinatol. 13:1993;123-127.
39. Weinstein M. R. Lithium treatment of women during pregnancy and the post-delivery period. Johnson F. N. Handbook of Lithium Therapy. 1980;421-429 MTP Press, Lancaster.
40. Mignot G., Devic M., Dumont M. Lithium and pregnancy. J Gynecol Obstet Biol Reprod. 7:1978;1303-1317.
41. Cohen L. S., Friedman J. M., Jefferson J. W. A reevaluation of risk of in utero exposure to lithium. JAMA. 271:1994;146-150.
42. Hall J. G., Pauli R. M., Wilson K. M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 68:1980;122-140.
43. Stevenson R. E., Burton O. M., Ferlauto G. J. Hazards of oral anticoagulants during pregnancy. JAMA. 243:1980;1549-1551.
44. Vitale N., De Feo M., De Santo L. S. Dose dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 33:1999;1637-1641.
45. O'Brien M. D., Gilmour-White S. Epilepsy and pregnancy. Br Med J. 307:1993;492-495.
46. Friis M. L., Holm N. V., Sindrup E. H. Facial clefts in sibs and children of epileptic patients. Neurology. 36:1986;346-350.
47. Shapiro S., Hartz S. C., Siskind V. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet. 1:1976;272-275.
48. Jager-Roman E., Deichl A., Jakob S. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr. 108:1986;997-1004.
49. Lammer E. J., Sever L. E., Oakley G. P. Jr. Teratogen update: valproic acid. Teratology. 35:1987;465-473.
50. Rosa F. W. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med. 324:1991;674-677.
51. Hanson J. W., Smith D. W. The fetal hydantoin syndrome. J Pediatr. 87:1975;285-290.
52. Scolnik D., Nulman I., Rovet J. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine Monotherapy. JAMA. 271:1994;767-770.
53. Nakane Y., Okuma T., Takahashi R. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia. 21:1980;663-680.
54. Lancet. 338:1991;131-137.
55. Nelson-Piercy, C. Handbook of obstetric medicine. Oxford, Isis Medical Media, 1997, 80, 94.
56. Rubin P. C. Beta-blockers in pregnancy. N Engl J Med. 305:1981;1323-1326.
57. Hopkinson H. Treatment of cardiovascular disease. Rubin P. C. Prescribing in pregnancy, 2nd edn. 1995;97-104 BMJ Publishing, London.
58. Gwee M. C. Can tetracycline-induced fatty liver in pregnancy be attributed to choline deficiency? Med Hypotheses. 9:1982;157-162.
59. Wenk R. E., Gebhardt F. C., Bhagavan B. S. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med. 26:1981;135-141.
60. Linseman D. A., Hampton L. A., Branstetter D. G. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol. 28:1995;59-64.
61. Aramayona J. J., Garcia M. A., Fraile L. J. Placental transfer of enrofloxacin and ciprofloxacin in rabbits. Am J Vet Res. 55:1994;1313-1318.
62. Berkovitch M., Pastuszak A., Gazarian M. Safety of the new quinolones in pregnancy. Obstet Gynecol. 84:1994;535-538.
63. Levy M., Spino M., Read S. E. Colchicine: a state-of-the-art review. Parmacotherapy. 11:1991;196-211.
64. Ben-Chetrit E., Levy M. Colchicine: 1998 update. Semin Arth Rheum. 28:1998;48-59.
65. Hanretty K. P., Whittle M. J. Identifying abnormalities. Rubin P. C. Prescribing in pregnancy, 2nd edn. 1995;8-21 BMJ Publishing, London.